Testing a new medication for childhood multiple sclerosis

Plain-English translation of NCT06408259 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , an oral medication taken by mouth, compared to , another established oral medication, in children and adolescents who have relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go). Researchers want to understand how well the medication works, how safe it is, and how the body processes it compared to the current standard treatment.

Currently, there are limited treatment options specifically studied and approved for younger patients with MS. This trial aims to find out if this medication could be a safe and effective choice for children and teens, potentially offering them another option to help manage their disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsing-remitting multiple sclerosis using current diagnostic criteria
you have experienced at least one MS attack in the past year, or two attacks in the past two years, or have evidence of active brain inflammation on an MRI scan
you are between childhood and adolescent age (specific age range per protocol)
your disability level is mild to moderate, measured on a standard MS disability scale

You likely don't qualify if…

you have progressive forms of multiple sclerosis rather than relapsing-remitting forms
you have other active immune system diseases besides MS
you have serious heart, liver, or other major organ disease
you are currently taking certain other medications that would interfere with this study

What participation looks like

You would be randomly assigned to take either the new medication or the established medication by mouth, and neither you nor your doctors would know which one you're taking at first. You would visit the clinic multiple times to have your blood tested, undergo MRI brain scans, and report how you're feeling. The study tracks both how well the medication controls your MS and any side effects you experience.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(33 sites)

United States

Local Institution - 0114, Loma Linda, California

University of California Davis Health, Sacramento, California

University of South Florida, Tampa, Florida

Local Institution - 0093, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois